Amarin Corp AMRN shares are trading higher on Wednesday after Piper Sandler initiated coverage on the company's stock with an Overweight rating and announced a $21 price target.
Amarin is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its products include Vascepa.
Amarin shares were trading up 6.59% at $7.12 on Wednesday during the time of publication. The stock has a 52-week high of $26.12 and a 52-week low of $3.95.
Related Links:
Verastem Shares Response Rate From COPIKTRA Data
FDA Approves Edesa's Dermatitis Treatment Study, Shares Up More Than 100%
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
